Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 753,317 shares of the medical research company’s stock after selling 51,943 shares during the period. Thermo Fisher Scientific accounts for approximately 0.9% of Ensign Peak Advisors Inc’s portfolio, making the stock its 21st largest position. Ensign Peak Advisors Inc owned 0.19% of Thermo Fisher Scientific worth $444,947,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mystic Asset Management Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Advanced Research Investment Solutions LLC lifted its position in Thermo Fisher Scientific by 213.3% in the first quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 32 shares during the last quarter. Lloyd Advisory Services LLC. lifted its position in Thermo Fisher Scientific by 294.1% in the first quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 50 shares during the last quarter. Tyler Stone Wealth Management purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $47,000. Finally, Lansing Street Advisors purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $47,000. Institutional investors and hedge funds own 86.50% of the company’s stock.

Insider Activity

In other news, CFO Stephen Williamson sold 12,300 shares of the stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $603.48, for a total value of $7,422,804.00. Following the sale, the chief financial officer now directly owns 43,944 shares in the company, valued at $26,519,325.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $588.36, for a total transaction of $5,883,600.00. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at $107,889,338.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Williamson sold 12,300 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the sale, the chief financial officer now owns 43,944 shares in the company, valued at approximately $26,519,325.12. The disclosure for this sale can be found here. Insiders have sold 55,397 shares of company stock worth $33,012,754 over the last ninety days. 0.43% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, July 29th. Barclays reduced their target price on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating for the company in a report on Monday. SVB Leerink upped their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday, July 29th. Finally, Credit Suisse Group started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, August 24th. They issued a “neutral” rating and a $675.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $655.64.

Thermo Fisher Scientific Trading Up 1.7 %

Shares of TMO opened at $579.19 on Tuesday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average is $567.33 and its two-hundred day moving average is $558.48. Thermo Fisher Scientific Inc. has a twelve month low of $497.83 and a twelve month high of $672.34. The firm has a market capitalization of $226.92 billion, a P/E ratio of 30.82, a PEG ratio of 1.77 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, topping the consensus estimate of $4.92 by $0.59. The company had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the prior year, the business posted $5.60 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be given a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.20 annualized dividend and a dividend yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio is presently 6.39%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.